• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management.

作者信息

Park Ji Eun, Yang Jieun, Han Sanghoon

机构信息

Ji Eun Park, Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju City, South Korea.

Jieun Yang, Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine, Jeju City, South Korea.

出版信息

Pak J Med Sci. 2025 Jul;41(7):2164. doi: 10.12669/pjms.41.7.12301.

DOI:10.12669/pjms.41.7.12301
PMID:40735561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12302082/
Abstract
摘要

相似文献

1
Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management.芦可替尼与乙型肝炎病毒再激活：一项需要预防性管理的临床关注问题。
Pak J Med Sci. 2025 Jul;41(7):2164. doi: 10.12669/pjms.41.7.12301.
2
Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms.鲁索替尼治疗骨髓增殖性肿瘤患者后乙肝病毒再激活的风险。
Hematology. 2021 Dec;26(1):460-464. doi: 10.1080/16078454.2021.1945234.
3
Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.接受免疫检查点抑制治疗的患者中乙肝病毒再激活：系统评价与荟萃分析
J Cancer Res Clin Oncol. 2023 May;149(5):1993-2008. doi: 10.1007/s00432-022-04133-8. Epub 2022 Jun 29.
4
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.系统评价与网状Meta分析：口服核苷（酸）类似物预防化疗引起的乙型肝炎病毒再激活的比较疗效
Oncotarget. 2016 May 24;7(21):30642-58. doi: 10.18632/oncotarget.8907.
5
Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.肺癌化疗期间的乙型肝炎病毒再激活及抗病毒预防：一项系统评价和荟萃分析。
PLoS One. 2017 Jun 22;12(6):e0179680. doi: 10.1371/journal.pone.0179680. eCollection 2017.
6
Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.预防性使用拉米夫定改善化疗期间HBsAg阳性淋巴瘤患者的预后：一项系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):80-92. doi: 10.1016/j.clinre.2014.07.010. Epub 2014 Sep 4.
7
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.生物治疗银屑病患者乙型肝炎和丙型肝炎病毒再激活的风险：回顾性队列研究和文献系统评价。
J Am Acad Dermatol. 2017 Jul;77(1):88-97.e5. doi: 10.1016/j.jaad.2017.01.037. Epub 2017 May 9.
8
Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.接受介入治疗联合酪氨酸激酶抑制剂及免疫检查点抑制剂的转化治疗的乙肝相关肝细胞癌患者术后乙肝病毒再激活及其对生存的影响
Front Cell Infect Microbiol. 2025 Jul 17;15:1598193. doi: 10.3389/fcimb.2025.1598193. eCollection 2025.
9
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.接受抗癌治疗的血液系统恶性肿瘤患者中乙型肝炎病毒再激活的预防与管理
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
10
Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.癌症患者接受免疫检查点抑制剂治疗后乙型肝炎病毒再激活：系统评价和荟萃分析。
Infect Dis Poverty. 2023 Sep 22;12(1):87. doi: 10.1186/s40249-023-01128-6.

本文引用的文献

1
Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib.接受鲁索替尼治疗的骨髓增殖性肿瘤患者发生乙型肝炎病毒再激活的风险。
World J Hepatol. 2023 Nov 27;15(11):1188-1195. doi: 10.4254/wjh.v15.i11.1188.
2
Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms.鲁索替尼治疗骨髓增殖性肿瘤患者后乙肝病毒再激活的风险。
Hematology. 2021 Dec;26(1):460-464. doi: 10.1080/16078454.2021.1945234.
3
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.鲁索替尼治疗骨髓纤维化患者后乙肝病毒感染再激活
Leukemia. 2014 Jan;28(1):225-7. doi: 10.1038/leu.2013.235. Epub 2013 Aug 9.